Bilateral grey-matter increase in the putamen in primary blepharospasm

J Neurol Neurosurg Psychiatry. 2006 Sep;77(9):1017-20. doi: 10.1136/jnnp.2005.087148. Epub 2006 May 11.

Abstract

Background: Primary blepharospasm is a focal dystonia characterised by excessive involuntary closure of the eyelids. The pathophysiology of primary blepharospasm is unresolved.

Aim: To pinpoint grey-matter changes that are associated with primary blepharospasm.

Methods: 16 right-handed patients with primary blepharospasm (mean age 67.4 (SD 4.3) years; 12 women) were compared with 16 healthy volunteers matched for sex and age. High-resolution T1-weighted magnetic resonance imaging of each participant was obtained and analysed by voxel-based morphometry, a method to detect regionally specific differences in grey matter between patients and control group. To evaluate whether the identified grey-matter changes were correlated with the duration of primary blepharospasm or botulinum neurotoxin treatment (BoNT), separate regression analyses were carried out.

Results: In patients with primary blepharospasm, grey-matter increase in the putamina was observed, whereas regression analyses did not indicate a correlation between grey-matter increases and the duration of primary blepharospasm or BoNT. Grey-matter decrease was detected in the left inferior parietal lobule; here regression analyses of grey-matter decrease showed a significant (p = 0.013) correlation of grey-matter decrease with the duration of BoNT.

Conclusions: The data suggest structural changes in primary blepharospasm and point to a crucial role of the putamen for the pathophysiology of this focal dystonia.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Blepharospasm / physiopathology*
  • Case-Control Studies
  • Female
  • Fluorodeoxyglucose F18
  • Functional Laterality
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Putamen / pathology*
  • Radiopharmaceuticals

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18